title: Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
abstract: BACKGROUND
  The addition of pertuzumab to trastuzumab and taxane therapy was shown to be an effective first-line treatment for patients with HER2-positive metastatic breast cancer.
  
  
  OBJECTIVE
  Describe the progression-free survival of pertuzumab, trastuzumab, and taxane therapy for previously treated HER2-positive metastatic breast cancer.
  
  
  METHODS
  This case-series reviews 19 patients with metastatic breast cancer receiving treatment with pertuzumab, trastuzumab, taxane after progression and exposure to previous lines of HER2-directed therapy. Progression-free survival and adverse effects such as changes in ejection fraction and episodes of neutropenic fever were assessed.
  
  
  RESULTS
  The median progression-free survival of pertuzumab, trastuzumab, taxane therapy for previously treated metastatic breast cancer was 4.1 months. The mean baseline left ventricular ejection fraction change experienced by patients was -1%. Neutropenic fever events were not encountered.
  
  
  CONCLUSIONS
  Pertuzumab, trastuzumab, and taxane therapy seems to confer progression-free survival benefit for previously treated metastatic breast cancer. The use of the dual anti-HER2 antibodies, pertuzumab and trastuzumab, in addition to cytotoxic chemotherapy agents for previously treated metastatic breast cancer should be further evaluated.
authors: Department of Pharmacy, University of California San Francisco Medical Center, San Francisco, CA, USA bao.dao@ucsf.edu.
authors: Bao D
authors: BD
authors: Dao
authors: Department of Pharmacy, University of California San Francisco Medical Center, San Francisco, CA, USA.
authors: Hansen
authors: H
authors: Ho
authors: Department of Pharmacy, University of California San Francisco Medical Center, San Francisco, CA, USA.
authors: Laura N
authors: LN
authors: Quintal
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage*; D000068878:Trastuzumab / Q000008:administration & dosage*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001952:Bridged-Ring Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab; C080625:taxane; C508053:ERBB2 protein, human; C485206:pertuzumab
keywords: Metastatic breast cancer; pertuzumab; trastuzumab